Bevacizumab - Uveitis

You are here : Home > Formulary Search > Bevacizumab - Uveitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Intravitreal injection

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

ICB

Off Label

SPC

Restrictions / Comments :

Important

2nd line option where intravitreal dexamethasone is contraindicated

Documentation

Evidence Review

Bevacizumab for Uveitis - Evidence Review - October 2013

PAD Profile

ChemicalSubstance :

Bevacizumab

Indication :

Uveitis

Group Name :

Keywords :

Brand Names Include :

Avastin

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Committee Recommendations (1)

30 Oct 13 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

PCN supported the use of bevacizumab as a second line treatment option for patients with non-infectious sight threatening or sight-losing intermediate or posterior uveitis who are unable to receive intravitreal dexamethasone (Ozurdex) due to a contraindication.

Other Indications

Below are listed other indications that Bevacizumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Uveitis.